prikaz prve stranice dokumenta Resistance to KRAS inhibition in advanced non-small cell lung cancer
  Download
PDF 1.61 MB
Scientific paper - Review paper
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Frontiers in Oncology, 14 (2024); 1357898. https://doi.org/10.3389/fonc.2024.1357898
Sreter, Katherina Bernadette; Catarata, Maria Joana; von Laffert, Maximilian; Frille, Armin

Cite this document

Sreter, K. B., Catarata, M. J., von Laffert, M. & Frille, A. (2024). Resistance to KRAS inhibition in advanced non-small cell lung cancer. Frontiers in Oncology, 14.. doi: 10.3389/fonc.2024.1357898

Sreter, Katherina Bernadette, et al. "Resistance to KRAS inhibition in advanced non-small cell lung cancer." Frontiers in Oncology, vol. 14, 2024. https://doi.org/10.3389/fonc.2024.1357898

Sreter, Katherina Bernadette, Maria Joana Catarata, Maximilian von Laffert and Armin Frille. "Resistance to KRAS inhibition in advanced non-small cell lung cancer." Frontiers in Oncology 14 (2024). https://doi.org/10.3389/fonc.2024.1357898

Sreter, K. B., et al. (2024) 'Resistance to KRAS inhibition in advanced non-small cell lung cancer', Frontiers in Oncology, 14. doi: 10.3389/fonc.2024.1357898

Sreter KB, Catarata MJ, von Laffert M, Frille A. Resistance to KRAS inhibition in advanced non-small cell lung cancer. Frontiers in Oncology [Internet]. 2024 [cited 2024 December 07];14. doi: 10.3389/fonc.2024.1357898

K. B. Sreter, M. J. Catarata, M. von Laffert and A. Frille, "Resistance to KRAS inhibition in advanced non-small cell lung cancer", Frontiers in Oncology, vol. 14, 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:139949. [Accessed: 07 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Resistance to KRAS inhibition in advanced non-small cell lung cancer
AuthorKatherina Bernadette Sreter
AuthorMaria Joana Catarata
AuthorMaximilian von Laffert
AuthorArmin Frille
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Lung cancer remains the leading cause of cancer death globally. More than 50% of new cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor survival of such patients. Mutations in the KRAS (Kirsten rat sarcoma virus) gene occur in nearly a third of lung adenocarcinoma and have for decades been deemed an ‘undruggable’ target. Yet, in recent years, a growing number of small molecules, such as the GTPase inhibitors, has been investigated in clinical trials of lung cancer patients harboring KRAS mutations, yielding promising results with improved outcomes. Currently, there are only two approved targeted therapies (adagrasib and sotorasib) for advanced or metastatic KRAS - mutated NSCLC from the second-line setting onwards. In this narrative review, we will focus on KRAS, its molecular basis, the role of its co-mutations, clinical evidence for its inhibition, putative mutation to resistance, and future strategies to overcome resistance to KRAS inhibition.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleFrontiers in Oncology
Numberingvol. 14, 1357898
e-ISSN2234-943X
DOIhttps://doi.org/10.3389/fonc.2024.1357898
URN:NBNurn:nbn:hr:220:139949
Publication2024
Document URLhttps://www.frontiersin.org/articles/10.3389/fonc.2024.1357898/full
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-09-25 12:38:03